Experts Reviewed Multiple Myeloma Treatment Data
Dr. Hans Lee and Dr. Douglas Sborov examined trial outcomes for patients with high-risk relapsed or refractory multiple myeloma.
Updated on Oct. 14, 2026 in Cancer
Dr. Hans Lee and Dr. Douglas Sborov recently discussed clinical trial results regarding the management of high-risk relapsed or refractory multiple myeloma. The analysis highlights current therapeutic options for patients presenting with high-risk cytogenetics and extramedullary disease.
Why it matters
High-risk multiple myeloma remains a significantly challenging population to treat, despite substantial recent clinical advances. Expert insights into subgroup data help clinicians better navigate complex treatment decisions for this vulnerable group.
Clinical trial subgroup analyses provide response data for BCMA-directed therapies across various high-risk patient populations. Researchers continue to evaluate efficacy benchmarks compared to established therapeutic standards.
The players
Dr. Hans Lee
He is a medical expert who participated in the analysis of clinical trial data for treating high-risk multiple myeloma.
Dr. Douglas Sborov
He is a medical professional who provided clinical insights alongside Dr. Lee regarding the management of relapsed and refractory disease.
The details
The analysis underscores the potential role of bispecific antibodies for patients with extramedullary disease and the application of CAR T-cell therapy for those with functionally high-risk disease. Clinicians utilize these subgroup findings to incorporate specific disease characteristics and patient preferences into treatment selection.
Timeline
The clinical discussion regarding multiple myeloma treatments was published on October 14, 2026.
The Big Picture
This discussion follows a pattern established by the CARTITUDE-2 trial in refining treatment approaches for high-risk patient cohorts. It highlights the evolving standard of care that increasingly relies on granular subgroup data to address the limitations of legacy therapeutic approaches.
Patients with high-risk multiple myeloma may benefit from treatment plans that are increasingly tailored to their specific cytogenetic and disease features. Clinicians can use these findings to discuss more nuanced therapy options, such as bispecific antibodies or CAR T-cell approaches, with their patients.
The takeaway
Clinicians must balance disease-specific characteristics with patient preferences when determining the best course of action for refractory myeloma. Staying informed on the latest subgroup data from major trials is essential for optimizing outcomes in high-risk scenarios.
Further reading
For more information on current treatment landscapes, explore the Cancer section.
Source note: This article includes information reported by OncLive.
